Intra-Cellular Therapies, Inc. (ITCI)
USD 131.87
(0.0%)
USD 131.87
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 430.62 Million USD | 87.34% |
| 2022 | 228.68 Million USD | 210.41% |
| 2021 | 73.67 Million USD | 257.02% |
| 2020 | 20.63 Million USD | 5054.46% |
| 2019 | -416.5 Thousand USD | -12.97% |
| 2018 | -368.67 Thousand USD | 99.53% |
| 2017 | -79.17 Million USD | 15.32% |
| 2016 | -93.5 Million USD | -193635.92% |
| 2015 | -48.26 Thousand USD | 99.77% |
| 2014 | -20.64 Million USD | -1.77% |
| 2013 | -20.29 Million USD | -64.05% |
| 2012 | -12.36 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 134.96 Million USD | 11.72% |
| 2024 Q3 | 159.85 Million USD | 6.55% |
| 2024 Q2 | 150.03 Million USD | 11.16% |
| 2023 Q4 | 120.8 Million USD | 3.53% |
| 2023 FY | 428.43 Million USD | 87.34% |
| 2023 Q1 | 87.98 Million USD | 9.1% |
| 2023 Q2 | 102.96 Million USD | 17.03% |
| 2023 Q3 | 116.68 Million USD | 13.32% |
| 2022 FY | 228.68 Million USD | 210.41% |
| 2022 Q4 | 80.64 Million USD | 22.15% |
| 2022 Q3 | 66.02 Million USD | 30.93% |
| 2022 Q2 | 50.42 Million USD | 59.57% |
| 2022 Q1 | 31.6 Million USD | 37.52% |
| 2021 Q4 | 22.97 Million USD | 17.21% |
| 2021 Q3 | 19.6 Million USD | 15.55% |
| 2021 FY | 73.67 Million USD | 257.02% |
| 2021 Q1 | 14.12 Million USD | 25.4% |
| 2021 Q2 | 16.96 Million USD | 20.13% |
| 2020 Q1 | 813.2 Thousand USD | 104.28% |
| 2020 FY | 20.63 Million USD | 5054.46% |
| 2020 Q2 | 1.74 Million USD | 114.87% |
| 2020 Q3 | 6.81 Million USD | 289.88% |
| 2020 Q4 | 11.26 Million USD | 65.32% |
| 2019 Q1 | -24.99 Million USD | 25.63% |
| 2019 Q4 | -19 Million USD | 10.94% |
| 2019 Q2 | -23.72 Million USD | 5.05% |
| 2019 Q3 | -21.33 Million USD | 10.07% |
| 2019 FY | -416.5 Thousand USD | -12.97% |
| 2018 Q4 | -33.6 Million USD | 5.12% |
| 2018 FY | -368.67 Thousand USD | 99.53% |
| 2018 Q3 | -35.41 Million USD | -9.19% |
| 2018 Q2 | -32.43 Million USD | -5.66% |
| 2018 Q1 | -30.7 Million USD | -14.04% |
| 2017 Q3 | -18.44 Million USD | -49.16% |
| 2017 Q2 | -12.36 Million USD | 42.34% |
| 2017 Q1 | -21.44 Million USD | -1.72% |
| 2017 FY | -79.17 Million USD | 15.32% |
| 2017 Q4 | -26.92 Million USD | -46.0% |
| 2016 Q4 | -21.08 Million USD | 11.85% |
| 2016 Q3 | -23.91 Million USD | 4.62% |
| 2016 FY | -93.5 Million USD | -193635.92% |
| 2016 Q1 | -23.43 Million USD | -2.62% |
| 2016 Q2 | -25.07 Million USD | -6.99% |
| 2015 Q2 | -17.7 Million USD | 4.96% |
| 2015 FY | -48.26 Thousand USD | 99.77% |
| 2015 Q4 | -22.83 Million USD | 19.76% |
| 2015 Q3 | -28.45 Million USD | -60.73% |
| 2015 Q1 | -18.62 Million USD | -60.94% |
| 2014 Q4 | -11.57 Million USD | -195.14% |
| 2014 Q2 | -2.49 Million USD | 6.43% |
| 2014 Q3 | -3.92 Million USD | -57.48% |
| 2014 FY | -20.64 Million USD | -1.77% |
| 2014 Q1 | -2.66 Million USD | 99.9% |
| 2013 Q2 | -7.14 Million USD | -64.09% |
| 2013 Q3 | -3.48 Million USD | 51.16% |
| 2013 Q1 | -4.35 Million USD | -2961.26% |
| 2013 FY | -20.29 Million USD | -64.05% |
| 2013 Q4 | -2.73 Billion USD | -78305.2% |
| 2012 Q4 | 152.17 Thousand USD | 0.0% |
| 2012 FY | -12.36 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | -41.048% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -1347.382% |
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | -32.025% |
| Cosmos Health Inc. | 4.34 Million USD | -9800.406% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 17966.952% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -489.356% |
| Cronos Group Inc. | 6.99 Million USD | -6059.797% |
| Incannex Healthcare Limited | 12 Thousand USD | -3588441.667% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 142220.462% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | -928.973% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 57856.428% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -5063.883% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -5063.883% |
| SCYNEXIS, Inc. | 124.51 Million USD | -245.836% |
| Safety Shot Inc | -74.45 Thousand USD | 578453.949% |
| Theratechnologies Inc. | 62.12 Million USD | -593.114% |
| Alpha Teknova, Inc. | 10.29 Million USD | -4082.449% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -4172.972% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 12.173% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -8975.342% |
| Dynavax Technologies Corporation | 182.11 Million USD | -136.455% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 2.388% |
| Radius Health, Inc. | 307.71 Million USD | -39.945% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -77634.214% |
| Alvotech | -69.42 Million USD | 720.3% |
| SIGA Technologies, Inc. | 122.09 Million USD | -252.705% |
| Shineco, Inc. | 882.16 Thousand USD | -48714.398% |
| Silver Spike Investment Corp. | 8.1 Million USD | -5214.653% |
| Journey Medical Corporation | 52.52 Million USD | -719.91% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -10174.582% |
| Embecta Corp. | 749.9 Million USD | 42.576% |
| Harrow Health, Inc. | 90.55 Million USD | -375.55% |
| Procaps Group, S.A. | 239.56 Million USD | -79.75% |
| Biofrontera Inc. | 16.62 Million USD | -2489.914% |
| DURECT Corporation | 6.83 Million USD | -6203.982% |
| PainReform Ltd. | -15 Thousand USD | 2870933.333% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 17.779% |
| OptiNose, Inc. | 62.35 Million USD | -590.613% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -13999.561% |
| Organogenesis Holdings Inc. | 309.79 Million USD | -39.005% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -1185.989% |
| ProPhase Labs, Inc. | 16.23 Million USD | -2551.795% |
| Phibro Animal Health Corporation | 312.48 Million USD | -37.806% |
| Procaps Group S.A. | 239.56 Million USD | -79.75% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -32974.117% |
| Viatris Inc. | 6.43 Billion USD | 93.312% |
| Rockwell Medical, Inc. | 8.7 Million USD | -4847.438% |
| Aytu BioPharma, Inc. | 54.58 Million USD | -688.893% |
| Tilray Brands, Inc. | 223.35 Million USD | -92.802% |
| PetIQ, Inc. | 252.74 Million USD | -70.383% |
| Talphera, Inc. | -4.89 Million USD | 8897.242% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 76.69% |
| Alimera Sciences, Inc. | 61.17 Million USD | -603.981% |
| Assertio Holdings, Inc. | 125.04 Million USD | -244.365% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 6322593.026% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -1488.026% |
| Hempacco Co., Inc. | -1.21 Million USD | 35518.104% |
| Alvotech | -69.42 Million USD | 720.3% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 39.31% |
| Kamada Ltd. | 52.59 Million USD | -718.792% |
| Currenc Group, Inc. | 17.35 Million USD | -2381.087% |
| Indivior PLC | 907 Million USD | 52.522% |
| Evoke Pharma, Inc. | 4.97 Million USD | -8549.258% |
| Flora Growth Corp. | 17.73 Million USD | -2327.698% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 17966.952% |
| Evolus, Inc. | 140.52 Million USD | -206.438% |
| HUTCHMED (China) Limited | 453.55 Million USD | 5.055% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | -25.193% |
| Akanda Corp. | 111.44 Thousand USD | -386287.496% |